-
the dynamics of therapy-resistance by combining advanced molecular biology method development to multi-omic single-cell analyses of both ex vivo models and clinical tumor specimens. Our novel, in-house
-
genetics, gene therapy, CRISPR-based gene editing, stem cell technologies, and translational disease modelling. We are particularly interested in developing treatments for retinal disorders prevalent in
Enter an email to receive alerts for mobile-developer "https:" positions